Ultimately, increased understanding of BACE1 and BACE2 expression and activity in pancreatic cancer will allow optimal selection of β-secretase inhibitors that have greater efficacy in reducing the viability of pancreatic cancer cells. The gene discussed is BACE2; the disease is familial pancreatic carcinoma.